Showing results (1-10 of 170) with videos related to
Sort By:
Pageof 17
Pharmaceutics|February 27, 2026
Inhaled Antibiotic and Biologic Formulations Targeting Pseudomonas aeruginosaProdip Kumar Baral, Jack Dummer, Daniel Pletzer, et al.The Journal of Antimicrobial Chemotherapy|February 24, 2026
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directionsRobiul Islam, Shyamal C Das, Daniel PletzerExpert Opinion on Drug Delivery|January 5, 2024
The quest to deliver high-dose rifampicin: can the inhaled approach help?Prakash Khadka, Jack Dummer, Philip C Hill, et al.International Journal of Pharmaceutics|July 10, 2018
Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatmentPrakash Khadka, Jack Dummer, Philip C Hill, et al.Expert Opinion on Drug Delivery|June 13, 2022
An expert opinion on respiratory delivery of high dose powders for lung infectionsBishal Raj Adhikari, Jack Dummer, Keith C Gordon, et al.Drug Delivery and Translational Research|September 21, 2022
A review of formulations and preclinical studies of inhaled rifampicin for its clinical translationPrakash Khadka, Jack Dummer, Philip C Hill, et al.International Journal of Pharmaceutics|July 15, 2020
A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatmentPrakash Khadka, Philip C Hill, Boya Zhang, et al.International Journal of Pharmaceutics|February 5, 2021
Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat modelPrakash Khadka, Shubhra Sinha, Ian G Tucker, et al.European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|February 27, 2021
Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley ratsPrakash Khadka, Shubhra Sinha, Ian G Tucker, et al.European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 14, 2022
Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulationBishal Raj Adhikari, Shubhra Sinha, Nikita Lyons, et al.Pageof 17